Roman Butler Fullerton & Co. Takes $675,000 Position in Exelixis, Inc. $EXEL

Roman Butler Fullerton & Co. acquired a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL) during the 1st quarter, HoldingsChannel reports. The institutional investor acquired 15,277 shares of the biotechnology company’s stock, valued at approximately $675,000.

A number of other large investors also recently bought and sold shares of EXEL. Anchor Investment Management LLC increased its holdings in shares of Exelixis by 500.0% in the 3rd quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 500 shares during the period. Motiv8 Investments LLC purchased a new stake in shares of Exelixis during the 4th quarter worth $26,000. Acumen Wealth Advisors LLC purchased a new stake in shares of Exelixis during the 4th quarter worth $29,000. Activest Wealth Management bought a new stake in Exelixis during the fourth quarter valued at about $32,000. Finally, Northwestern Mutual Wealth Management Co. grew its stake in Exelixis by 1,380.4% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 773 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

Exelixis Stock Performance

Exelixis stock opened at $57.10 on Friday. The stock has a 50-day moving average of $51.47 and a two-hundred day moving average of $46.39. Exelixis, Inc. has a one year low of $33.76 and a one year high of $57.57. The stock has a market cap of $14.35 billion, a PE ratio of 18.97, a price-to-earnings-growth ratio of 1.62 and a beta of 0.42.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.75 by $0.12. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The business had revenue of $610.81 million for the quarter, compared to analyst estimates of $607.51 million. During the same quarter in the previous year, the firm earned $0.55 earnings per share. The company’s revenue was up 10.0% on a year-over-year basis. As a group, sell-side analysts predict that Exelixis, Inc. will post 3.16 EPS for the current fiscal year.

Insider Buying and Selling

In other Exelixis news, EVP Patrick J. Haley sold 32,110 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $49.81, for a total transaction of $1,599,399.10. Following the transaction, the executive vice president owned 357,638 shares in the company, valued at approximately $17,813,948.78. This represents a 8.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Dana Aftab sold 43,451 shares of the firm’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $50.35, for a total transaction of $2,187,757.85. Following the completion of the transaction, the executive vice president directly owned 594,741 shares of the company’s stock, valued at approximately $29,945,209.35. This represents a 6.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 219,170 shares of company stock worth $10,620,641 over the last ninety days. Company insiders own 2.60% of the company’s stock.

Analyst Upgrades and Downgrades

EXEL has been the subject of a number of recent research reports. Royal Bank Of Canada boosted their target price on shares of Exelixis from $43.00 to $46.00 and gave the stock a “sector perform” rating in a report on Tuesday. Weiss Ratings raised shares of Exelixis from a “buy (b)” rating to a “buy (b+)” rating in a research report on Wednesday. UBS Group reiterated a “buy” rating on shares of Exelixis in a research note on Thursday, July 2nd. Citizens Jmp increased their target price on shares of Exelixis from $50.00 to $55.00 and gave the company a “market outperform” rating in a research report on Wednesday, June 24th. Finally, TD Cowen raised their target price on shares of Exelixis from $51.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Nine research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $47.93.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.